of MorphoSys

You are here

MorphoSys was founded in Martinsried near Munich in 1992. The founders included Dr. Simon Moroney, today’s CEO of the Company and Prof. Dr. Andreas Plückthun. Today, MorphoSys is one of the world’s leading biotechnology companies in the area of fully human antibodies.


Company founded in Martinsried/Munich, Germany


First commercial partnership with Pharmacia-Upjohn

Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried


MorphoSys achieves a settlement of the CAT patent dispute

Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany)


Start of a strategic partnership with Novartis

Presentation of the new research antibodies division, Antibodies by Design

Inclusion in the technology index TecDAX

MorphoSys achieves break even


The first HuCAL antibodies used in clinics

Acquisition of Biogenesis Group strengthens the research segment

First partnership with a Japanese pharmaceutical group


Acquisition of Serotec Group further strengthens the research segment

HuCAL antibodies to combat Alzheimer’s disease are used in clinics


MorphoSys announces development of new antibody platform technology

MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations


MorphoSys signs first infectious disease alliance with Daiichi-Sankyo


First proprietary therapeutic antibody in a patient setting

First in-licensing of a clinical antibody from Xencor

Aquisition of Sloning BioTechnology

MorphoSys presents new antibody technology arYla


MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL

With gantenerumab from Roche, the first partnered antibody program reaches late stage development

MorphoSys celebrates its 20th anniversary

MorphoSys signs first Ylanthia-based therapeutic partnership


MorphoSys and Emergent BioSolutions announce the beginning of a joint clinical phase 1 trial of MOR209/ES414 in patients with metastatic, castration-resistant prostate cancer (mCRPC).


MorphoSys licensee Janssen submits an application seeking approval of guselkumab for the treatment of moderate to severe plaque psoriasis in the US (FDA) and Europe (EMA).

MorphoSys moves to new company headquarter in Semmelweisstraße in Planegg.


MorphoSys celebrates its 25th anniversary.
MorphoSys's licensee Janssen received approval for Tremfya(R) (guselkumab) for the treatment of moderate-to-severe plaque psoriasis in the U.S., Europe and Canada.

MorphoSys's receives FDA breakthrough therapy designation for its proprietary lymphoma antibody MOR208 for the treatment of R/R DLBCL.


MorphoSys IPO at Nasdaq